Acknowledging Patient Heterogeneity in Economic Evaluation A Systematic Literature Review

Citation for published version (APA):

Grutters, J. P. C., Sculpher, M., Briggs, A. H., Severens, J. L., Candel, M. J., Stahl, J. E., De Ruyscher, D., Boer, A., Ramaekers, B. L. T., & Joore, M. A. (2013). Acknowledging Patient Heterogeneity in Economic Evaluation A Systematic Literature Review. *Pharmacoeconomics*, 31(2), 111-123. <https://doi.org/10.1007/s40273-012-0015-4>

Document status and date:

Published: 01/01/2013

DOI:

[10.1007/s40273-012-0015-4](https://doi.org/10.1007/s40273-012-0015-4)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 26 Apr. 2023

Acknowledging Patient Heterogeneity in Economic Evaluation

A Systematic Literature Review

Janneke P. C. Grutters · Mark Sculpher · Andrew H. Briggs · Johan L. Severens ·
Math J. Candel · James E. Stahl · Dirk De Ruyscher · Albert Boer ·
Bram L. T. Ramaekers · Manuela A. Joore

Published online: 4 January 2013
© Springer International Publishing Switzerland 2012

Abstract

Background and Objective Patient heterogeneity is the part of variability that can be explained by certain patient characteristics (e.g. age, disease stage). Population reimbursement decisions that acknowledge patient heterogeneity could potentially save money and increase population health. To date, however, economic evaluations pay only limited attention to patient heterogeneity. The objective of the present paper is to provide a comprehensive overview of the current knowledge regarding patient heterogeneity within economic evaluation of healthcare programmes.

Methods A systematic literature review was performed to identify methodological papers on the topic of patient

heterogeneity in economic evaluation. Data were obtained using a keyword search of the PubMed database and manual searches. Handbooks were also included. Relevant data were extracted regarding potential sources of patient heterogeneity, in which of the input parameters of an economic evaluation these occur, methods to acknowledge patient heterogeneity and specific concerns associated with this acknowledgement.

Results A total of 20 articles and five handbooks were included. The relevant sources of patient heterogeneity (demographics, preferences and clinical characteristics) and the input parameters where they occurred (baseline risk, treatment effect, health state utility and resource

J. P. C. Grutters (✉)
Department of Health Evidence, Radboud University
Nijmegen Medical Centre, P.O. Box 9101, 6500 Nijmegen,
The Netherlands
e-mail: J.Grutters@ebh.umcn.nl

M. Sculpher
Centre for Health Economics, University of York, York, UK

A. H. Briggs
Centre for Population Health Sciences, University of Glasgow,
Glasgow, UK

J. L. Severens
Institute of Health Policy and Management,
Erasmus University Rotterdam, Rotterdam, The Netherlands

M. J. Candel
Department of Methodology and Statistics, School for Public
Health and Primary Care (CAPHRI), Maastricht University,
Maastricht, The Netherlands

J. E. Stahl
Massachusetts General Hospital Institute for Technology
Assessment, Boston, MA, USA

D. De Ruyscher
Department of Radiation Oncology (Maastricht Clinic), Maastricht
University Medical Centre, Maastricht, The Netherlands

A. Boer
Dutch Health Care Insurance Board (CvZ), Diemen,
The Netherlands

B. L. T. Ramaekers · M. A. Joore
Department of Health Services Research, School for Public
Health and Primary Care (CAPHRI), Maastricht University,
Maastricht, The Netherlands

M. A. Joore
Department of Clinical Epidemiology and Medical Technology
Assessment, Maastricht University Medical Centre,
Maastricht, The Netherlands

utilization) were combined in a framework. Methods were derived for the design, analysis and presentation phases of an economic evaluation. Concerns related mainly to the danger of false-positive results and equity issues.

Conclusion By systematically reviewing current knowledge regarding patient heterogeneity within economic evaluations of healthcare programmes, we provide guidance for future economic evaluations. Guidance is provided on which sources of patient heterogeneity to consider, how to acknowledge them in economic evaluation and potential concerns. The improved acknowledgement of patient heterogeneity in future economic evaluations may well improve the efficiency of healthcare.

Key Points for Decision Makers

- Patient heterogeneity not only impacts relative treatment effects: its impact on baseline risk, utility and resource utilization should be acknowledged in economic evaluations
- General sources of patient heterogeneity are demographics, preferences and clinical characteristics
- Different methods for acknowledging patient heterogeneity in an economic evaluation are available for the design, analysis and presentation phases
- Potential equity concerns and resulting opportunity losses associated with acknowledging heterogeneity in economic evaluations should be presented

1 Introduction

Heterogeneity can be defined as ‘diversity in character or content’ [1]. In medical research, heterogeneity is depicted as the part of variability (the natural variation between patients) that can be explained by certain patient characteristics, such as age or stage of the disease [2]. This type of heterogeneity, which is referred to as patient heterogeneity, may influence the cost effectiveness of a treatment. Patient heterogeneity should be distinguished from differences in the nature of the treatment (e.g. different drug doses or different techniques used) or in the geographical region (transferability) that may impact cost effectiveness. These factors relate more to the generalizability of cost-effectiveness results [3] and are beyond the scope of this paper. The present paper collects available knowledge on acknowledging patient heterogeneity in the economic evaluation of healthcare programmes.

In healthcare, it has been recognized that patients differ in their response to treatment. Therefore, treatments are becoming increasingly tailored to the individual patient [4, 5]. At the same time, average results of economic

evaluations for patient groups are used to assist population reimbursement decisions upon new healthcare programmes [6, 7]. Average population-based economic evaluations, however, can mask important sources of patient heterogeneity within a patient population that may be important to improve population reimbursement decisions [7, 8]. For example, a programme that is deemed cost effective for a subpopulation may not be reimbursed because another subpopulation has a poorer outcome, and therefore on average it is not cost effective for all patients with that particular disease. This would result in health benefits forgone, as a subgroup of patients does not receive the optimal treatment. Or, inefficiency occurs because a programme is reimbursed based on its average cost effectiveness for the total population, while it may not be cost effective for a subpopulation of these patients. This would result in suboptimal use of scarce resources. Hence ignoring patient heterogeneity could be costly both in monetary terms and in health gain. Coyle et al. [9] for example showed that by acknowledging patient heterogeneity in the treatment of acute myocardial infarction a considerable monetary gain could be achieved. Basu and Meltzer [10] calculated that acknowledging patient heterogeneity in prostate cancer patients in the USA could even result in US\$70 million gained annually. They argue that the value of reflecting patient heterogeneity in reimbursement decisions can be far greater than the value of improved decision making at the population level [10]. Population reimbursement decisions that acknowledge patient heterogeneity could save money and increase population health. Obviously, this is only possible if the patient heterogeneity is known at the moment a treatment decision is made. This paper therefore focuses on observed patient heterogeneity, on which population reimbursement decisions could be based.

To date, only limited attention is paid in economic evaluations to patient heterogeneity. In clinical studies patient heterogeneity is often examined in terms of treatment effect [6, 7]. It is then examined whether heterogeneity exists in the relative treatment effect, using measures like relative risks, odds ratios or hazard ratios. This information, however, is insufficient for economic evaluations, as homogeneity in treatment effects from a clinical point of view does not necessarily imply homogeneity in cost effectiveness [6]. However, there is no systematic overview of which sources of patient heterogeneity exist and in which of the input parameters of an economic evaluation they may occur. Additionally, pharmacoeconomic guidelines provide hardly any methodological guidance on acknowledging heterogeneity [11]. Moreover, reflecting patient heterogeneity in reimbursement decisions may have ethical implications if it leads to limiting financial access to certain groups of individuals. For example, it is

questionable whether policy makers are willing to reimburse a treatment only for a subgroup of patients, when this subgroup is based on race [12].

The objective of the present paper is to provide a comprehensive overview of the current knowledge regarding patient heterogeneity within economic evaluations of healthcare programmes. More specifically, we aim to address the following research questions:

1. Which sources of patient heterogeneity can be relevant in economic evaluation and in which of the input parameters of an economic evaluation can they occur?
2. Which methods can be used for acknowledging patient heterogeneity in an economic evaluation?
3. What concerns exist with regard to acknowledging patient heterogeneity in economic evaluation and population reimbursement decisions?

2 Methods

2.1 Search Strategy and Selection Criteria

A systematic literature review was performed to identify methodological papers on the topic of patient heterogeneity in economic evaluation. We used the electronic database PubMed to search for peer-reviewed full papers, published before 2011. The electronic search term was as follows: ('heterogeneity') and ('cost-effectiveness' or 'economic evaluation'). Additional references were searched through manual searches of the reference lists of retrieved papers and specialist journals, and through discussion with the authors. Studies were included only if they were written in English, had an explicit methodological objective (i.e. objective, keywords or publication type includes 'methodology' or 'methods'; or objective is to 'discuss', 'propose', 'develop', or 'argue for change in economic evaluation'), and considered patient heterogeneity that is potentially known at the time of treatment decision. Papers were excluded if the main goal was to report outcomes, if they concerned heterogeneity not related to patients (e.g. heterogeneity in the nature of the treatment or issues relating to transferability) or if they concerned other methodological issues. Two authors (MJ, JG) independently reviewed the titles, abstracts and, if necessary, full papers, to determine whether a paper met the inclusion criteria. Discrepancies were solved by all authors in a consensus meeting. Additionally, handbooks on economic evaluation were searched for recommendations on patient heterogeneity. Expert consensus by all authors was used to determine whether the most important papers and handbooks were included.

2.2 Data Extraction and Analysis

Relevant data were extracted from the publications by two authors (JG, MJ) independently. First, for all included publications we retrieved the sources of patient heterogeneity that were mentioned in their examples, and in which of the input parameters of an economic evaluation this heterogeneity occurred. With input parameters, we refer to the data inputs of an economic evaluation in general, be it a trial-based or a model-based economic evaluation. Subsequently, these sources and input parameters were combined in a framework, in order to allow for a systematic consideration of patient heterogeneity in economic evaluations. Second, from the publications that explicitly mentioned methods to acknowledge patient heterogeneity, we extracted these methods. Methods were categorized into methodology for the design (e.g. choosing trial outcomes, collecting model input parameters, designing model structure), analysis (e.g. analysing costs, effects, cost effectiveness, uncertainty) and presentation (e.g. presentation of costs, effects, cost effectiveness, uncertainty) phases of an economic evaluation [6]. Methods were extracted for both trial-based and model-based economic evaluations. If a method is only useful for one type of economic evaluation (model or trial), this is specified. Third, we extracted specific concerns that were mentioned with regard to acknowledging patient heterogeneity. Discrepancies were solved in a consensus meeting with the authors.

3 Results

3.1 Selected Sources and Characteristics

On the basis of the keywords, 231 articles were found (Fig. 1). A total of 220 articles were excluded because they were not deemed relevant, which left a total number of eleven studies included in the review [7–10, 13–19]. Most excluded references reported on heterogeneity between studies or differences in the nature of treatment instead of patient heterogeneity. Five additional articles were retrieved through manual searches of the reference lists and discussion with the authors [12, 20–23]. Four additional publications were included because they were responses to the included references [24–27]. The 20 included studies were published between 2001 [23] and 2010 [22]. Five handbooks on economic evaluation were included in the review [2, 6, 29, 48, 49]. All included publications are listed in Table 1.

3.2 Sources of Patient Heterogeneity

Table 1 summarizes the sources of patient heterogeneity that were used as examples in the included publications.

Fig. 1 Flow diagram of the search results

The columns describe the input parameters of an economic evaluation where the patient heterogeneity occurred in the examples.

Based on Table 1 we developed a framework to systematically consider patient heterogeneity in economic evaluations. Economic evaluations consider both costs and effects. Regarding the costs, patient heterogeneity will not occur in unit costs, as these are likely to be independent of patient characteristics. Differences in unit costs are more likely a result of differences between jurisdictions, which is an issue of transferability [28]. Resource utilization, however, may well be affected by characteristics of the patient. Regarding the effects, from Table 1 it was clear that there may be patient heterogeneity in baseline risk (e.g. treatment-independent probability of a clinical event, mortality rate, incidence), treatment effect and health state utility. Heterogeneity in the treatment effect is the most recognized form of heterogeneity, as it is also examined in

clinical studies. This mostly refers to heterogeneity in relative treatment effects such as relative risks, odds ratios or hazard ratios. Heterogeneity in baseline risk and health state utility refers to absolute effects, which are also of importance in economic evaluations.

Demographic characteristics of a patient, such as age, sex, intelligence and race, may be a source of patient heterogeneity. Preferences may also be a source of heterogeneity, for example because of differences in beliefs, attitude or risk tolerance. Finally, several clinical characteristics that relate to the disease were mentioned as a source of heterogeneity, such as severity, disease history and genetic profile. In the framework, we consider genetic factors such as pharmacogenetic heterogeneity to be clinical characteristics. The framework to consider patient heterogeneity in economic evaluations therefore consists of three general sources of patient heterogeneity (demographics, preferences and clinical characteristics) that may

Table 1 Overview of the included publications and the source of patient heterogeneity described

Study	Publication type	Probability of clinical event (independent of treatment)	Mortality rate	Incidence	Treatment effect	Health state utility	Resource utilization	Cost-effectiveness outcome
Bala and Zarkin [13]	Original article				Genetics	Preferences	Genetics	
Bala and Zarkin [24]	Response ^a					Preferences		
Basu and Meltzer [10]	Original article							Age; co-morbidity; disease history
Brennan et al. [14]	Original article							
Briggs et al. [2]	Handbook	Age; cholesterol; previous myocardial infarction; sex	Age; sex			Age; sex	Age	
Coyle et al. [9]	Original article							Location of myocardial infarction; age
Drummond et al. [6]	Handbook	Age; sex; risk profile			Risk profile			
Fox-Rushby and Cairns [48]	Handbook				Age	Symptoms	Age	
Glick et al. [29]	Handbook						Disease severity	
Gold et al. [49]	Handbook				Age	Preferences		
Heeg et al. [15]	Original article			Age				
Hoch et al. [12]	Original article							
Hoch and Dewa [16]	Original article							Disease severity
La Caze [25]	Response ^a	Genetics			Genetics			Race
Marshall and Hux [17]	Original article				Patient characteristics			Race
Nixon and Thompson [21]	Original article				Intelligence		Prior resource utilization	
Robinson and Parkin [26]	Response ^b					Preferences		
Sculpher and Gafni [23]	Original article					Preferences		
Sculpher and Gafni [27]	Response ^b							
Sculpher [7]	Original article	Age; presence of diabetes mellitus; previous diabetic events	Age		Preferences	Previous myocardial infarction; preferences; age	Weight (dosage)	
Sculpher [22]	Original article	Age; sex; history of previous events						
Spiegelhalter and Best [18]	Original article		Age; sex					

Table 1 continued

Study	Publication type	Probability of clinical event (independent of treatment)	Mortality rate	Incidence	Treatment effect	Health state utility	Resource utilization	Cost-effectiveness outcome
Stevens and Normand [8]	Original article							Age; co-morbidity; distance from health facility
Willan et al. [20]	Original article							
Zaric [19]	Original article	Risk profile					Race	

^a Response to Bala and Zarkin [13]^b Response to Sculpher and Gafni [23]

impact four input parameters of economic evaluations (baseline risk, treatment effect, health state utility and resource utilization) [Fig. 2].

3.3 Methodology to Acknowledge Patient Heterogeneity

Sixteen publications describe methodology to acknowledge heterogeneity in the design, analysis or presentation phase of an economic evaluation [2, 6, 7, 9, 10, 12, 14–21, 23, 29]. In any economic evaluation, stratified analyses of cost effectiveness (in the most extreme case stratified to $N = 1$) are needed to inform whether patient heterogeneity should be reflected in the reimbursement decision. The identified methodologies can be used to allow for such stratified analyses. Six publications describe methodology for use in the design phase [2, 14, 15, 18, 19, 23]. The most comprehensive methodology to acknowledge patient heterogeneity in an economic evaluation in this phase is provided by Briggs et al. [2]. They provide detailed guidance as to how regression methods can be used in a decision model to relate input parameters (e.g. survival, event probability) to a patient characteristic. These methods can be used in models that simulate cohorts of patients as well as in models that simulate individual patients. The authors describe a number of regression models that can be used depending on the nature of the data [2]. In line with this, three publications propose to use different input values for different subgroups of patients [18, 19, 23]. Both Brennan et al. [14] and Heeg et al. [15] state that stratified analyses are possible to acknowledge heterogeneity in models that simulate cohorts of patients, but this may not be ideal depending on the size of the model and the number of subgroups. Brennan et al. [14] describe that different subgroups (based on, for example, baseline risk) can start out in different health states. This way one can take into account that a specific course of action may differ depending on the baseline risk, by explicitly modelling this conditional on the health state. In case this technique becomes too complex, patient-level simulation provides a useful alternative to a cohort model [14]. However, stratified analyses will still be needed to inform whether patient heterogeneity should be reflected in the reimbursement decision.

Nine publications propose specific methods for the analysis phase of an economic evaluation [6, 9, 10, 12, 16, 17, 20, 21, 29]. When individual patient data are available on costs, effects and patient characteristics, the existence of patient heterogeneity can be analysed through the use of regression techniques. Hoch et al. [12] were the first to propose that regression analysis could be used within the net benefit framework. Two years later, the same authors further developed the regression approach to cost-

		Sources of patient heterogeneity		
Input parameters in health economic evaluation		Demographics	Preferences	Clinical characteristics
		<i>e.g. age gender income</i>	<i>e.g. attitude beliefs risk tolerance</i>	<i>e.g. disease severity disease history genetic profile</i>
	Baseline risk			
	Treatment effect			
	Health state utility			
	Resource utilization			

Fig. 2 Overview of the sources of patient heterogeneity that can be relevant in economic evaluation, and the input parameters where they may occur

effectiveness analysis by proposing the use of a system of seemingly unrelated regression equations [20]. This approach has the advantage of allowing different co-variables and functional forms for the two equations (for costs and effects). Nixon and Thompson [21] further developed this regression approach by proposing a coherent set of Bayesian methods that consider costs and effects jointly, and that allow for the usual skewness of cost data. Drummond et al. [6], Hoch and Dewa [16] and Marshall and Hux [17] all propose regression methods to explore subgroups, referring to the above-mentioned studies. Glick et al. [29] also propose regression techniques, but only to examine whether there is heterogeneity in the costs. It should be noted that the use of regression techniques informs about the subgroups that are statistically significant, but these techniques do not pronounce on the clinical relevance and relevance with regard to costs of a subgroup for reimbursement decisions. Additionally, regression techniques can lead to false-positive results if many subgroups are investigated or if they are not specified in advance of looking at the data [21].

Coyle et al. [9] propose to quantify the efficiency gains resulting from subgroup policy, which relates more to the relevance of potential subgroups. They provide a framework to calculate the net monetary benefit (NMB) of different subgroup policies, to examine whether subgroup policy is valuable and which subgroup policy is the most valuable. When comparative data on costs and effects are available for each individual patient, the expected value of individualizing care (EVIC) can be calculated. In this technique, proposed by Basu and Meltzer [10], the value of optimal decision making based on population-based averages is compared with the value of incorporating individual-level values of heterogeneous parameters (in their example individual preferences) in the decision-making

process. They calculate the monetary gain that can be obtained through giving patients the treatment that is cost effective for that particular individual patient, compared with giving patients the treatment that is on average cost effective.

In the presentation of an economic evaluation, Briggs et al. [2] propose to present full results, including multiple cost-effectiveness acceptability curves, for subgroups of patients. Additionally, it is advised to present possible equity constraints that may be relevant, and their resulting opportunity losses [7, 9]. For example, if there are potential equity concerns regarding subgroup policy based on age, this should be presented, as well as the opportunity losses associated with (not) reimbursing the treatment for all age groups [9].

All methods are listed in Table 2. They are illustrated by hypothetical examples concerning the economic evaluation of treatments in non-small-cell lung cancer.

3.4 Concerns With Regard to Acknowledging Patient Heterogeneity

Nine studies specifically describe potential concerns associated with acknowledging patient heterogeneity [6–9, 13, 20, 21, 24, 25]. Four publications caution for *post hoc* stratified analyses and the potential of misleading results and provide some requirements to avoid such misleading results [6, 8, 20, 21]. Drummond et al. [6] for example state that there should always be a plausible clinical explanation for differences between subgroups of patients, rather than crude data mining. Nixon and Thompson [21] in their paper also note the danger of false-positive results if many subgroups are investigated or if they are not specified in advance of looking at the data. This danger of

Table 2 Overview of methods for acknowledging patient heterogeneity

Study	Publication type	Description	Example: economic evaluation of treatment for NSCLC
<i>Design phase</i>			
Briggs et al. [2]	Handbook	Link decision model input parameters to pt characteristics, ideally using regression	In a decision model, the recurrence rate is a function of tumour size
Zaric [19]	Original article	Use different inputs in a decision model (e.g. baseline risk) for different subgroups	In a decision model, pts with small tumours have a different recurrence rate than pts with large tumours
Spiegelhalter and Best [18]	Original article	Use different inputs in a decision model (e.g. baseline risk) for different subgroups	
Sculpher and Gafni [23]	Original article	Use different health state utility values in a decision model for different subgroups	In a decision model, pts with a poor performance status are assigned lower utility values than pts with good performance status
Brennan et al. [14]	Original article	Subdivide health states in decision model/pt-level simulation if this becomes too complex	In a decision model, recurrence status are subdivided based on tumour size and performance status. If more pt characteristics are included and this becomes too complex, pt-level simulation is performed and each pt is assigned a tumour size, performance status, and other relevant characteristics
Heeg et al. [15]	Original article	Subdivide health states in decision model/pt-level simulation if this becomes too complex	
<i>Analysis phase</i>			
Hoch et al. [12]	Original article	Regression techniques with NMB as dependent variable to identify/define subgroups	Examine with regression analysis whether tumour size significantly impacts the NMB of a treatment
Willan et al. [20]	Original article	Regression techniques with costs and effects as dependent variables to identify/define subgroups	Examine with regression analysis whether tumour size significantly impacts the costs and effects of a treatment
Nixon and Thompson [21]	Original article	Regression techniques with costs and effects as dependent variables to identify/define subgroups	Examine with regression analysis whether tumour size significantly impacts the costs, effects and/or NMB of a treatment
Drummond et al. [6]	Handbook	Regression techniques to identify/define subgroups (as described in Hoch et al. [12] and Willan et al. [20])	
Hoch and Dewa [16]	Original article	Regression techniques to identify/define subgroups (as described in Hoch et al. [12])	Examine with regression analysis whether tumour size significantly impacts the NMB of a treatment
Marshall and Hux [17]	Original article	Regression techniques to identify/define subgroups (as described in Nixon and Thompson [21])	Examine with regression analysis whether tumour size significantly impacts the costs and effects of a treatment
Glick et al. [29]	Handbook	Regression techniques with costs as dependent variable to identify/define subgroups	Examine with regression analysis whether tumour size significantly impacts the costs of a treatment
Coyle et al. [9]	Original article	Quantify value of subgroup policy	Quantify the gain in NMB of giving pts with small tumours a different treatment than pts with large tumours
Basu and Meltzer [10]	Original article	Quantify value of individualized care	Quantify the value of basing treatment choice on individual pts, based on their tumour size, performance status and other potentially relevant characteristics, instead of giving one treatment to all pts

Table 2 continued

Study	Publication type	Description	Example: economic evaluation of treatment for NSCLC
<i>Presentation phase</i>			
Briggs et al. [2]	Handbook	Present results of full economic evaluation including uncertainty analyses for subgroups	Present costs, effects, ratios and acceptability curves for pts with small tumours and separately for pts with large tumours
Coyle et al. [9]	Original article	Present possible equity constraints and resulting opportunity loss	Present the loss in NMB when one treatment is given to all pts because a policy where the choice of treatment depends on tumour size is not considered equitable
Sculpher [7]	Original article	Present possible equity constraints and resulting opportunity loss (as described in Coyle et al. [9])	
<i>NMB net monetary benefit, NSCLC non-small-cell lung cancer, $pt(s)$ patient(s)</i>			

false-positive results is also briefly mentioned by Stevens and Normand [8], who further state that this is more a statistical problem than an economic one. That is, subgroups should not only be statistically significant, but also relevant for reimbursement decisions. In this light, Willan et al. [20] mention that the role of stratified analysis in economic evaluation should be explored in terms of its importance for policy purposes in comparison with the usual reluctance to undertake stratified analyses in clinical evaluation.

Additionally, in a comment to the paper by Bala and Zarkin [13], La Caze [25] states that pharmacogenomics provides a challenge to fundamental principles that underlie most systems for deciding which drugs should be publicly subsidized. The author provides no solution, but states that ‘discussion and debate are required to navigate a line between the extremes while giving due consideration to both equality and utility’ [25], which was subsequently agreed upon by Bala and Zarkin [24]. While this discussion is specific to pharmacogenomics, acknowledging heterogeneity in general may cause equity concerns. Sculpher [7] for example mentions that there may be equity constraints on which subgroups are used for reimbursement decisions. In particular, the use of sociodemographic characteristics to determine which subgroups should have access to a technology may be considered inequitable. However, this will depend on whether, for example, a subgroup with a higher age actually experiences a lower treatment effect, or they merely have less years of life left and consequently less QALYs to gain. Also, it may for example be more acceptable to use subgroup policy based on race when race for biological reasons impacts the effect of a treatment, than if race only impacts cost effectiveness through resource utilization as was found by Willan et al. [20]. This emphasizes the importance of clarity regarding which input parameter of an economic evaluation is impacted by the patient heterogeneity. As was shown by Coyle et al. [9], equity constraints can impose costs in terms of health benefits forgone. They propose a framework to quantify the costs of these possible equity constraints by calculating the expected opportunity loss (net benefit loss) when gains from stratification cannot be fully realized due to equity constraints or professional non-adherence. However, they do not seek to determine what are and what are not suitable grounds for the stratification of patients. Sculpher [7] also mentions that the use of preference subgroups would raise equity issues. This is for example the case when preferences differ because of the income of respondents [23]. This equity concern is emphasized by Robinson and Parkin [26] in a comment on Sculpher and Gafni’s paper [23]. They state that preference subgroups conflict with the idea that societal welfare is to be determined by aggregation of the preferences of that society. In a reply, Sculpher and

Gafni [27] dispute this conflict because their method uses societal preferences. The critique is however relevant when individual preferences are used, as was proposed in two of the included papers [10, 13].

4 Discussion

To the best of our knowledge, our paper is the first to systematically review the current knowledge on acknowledging observed patient heterogeneity in economic evaluation. We found that patient heterogeneity may relate to patient demographics, their preferences or clinical characteristics, and that it can impact baseline risk, treatment effect, health state utility and resource utilization. We have developed a framework that allows researchers and policy makers to systematically explore which source of patient heterogeneity could be relevant in each of the input parameters of an economic evaluation. Additionally, we have listed the various methods that can be used to account for patient heterogeneity, such as linking inputs to patient characteristics, regression methods and quantifying the value of subgroup or individualized policy. Finally, we have summarized the statistical and ethical concerns that may be related to acknowledging patient heterogeneity in population reimbursement decisions. Our results can provide guidance for researchers to systematically acknowledge heterogeneity in their assessments. Also, they can assist policy makers in requesting relevant evidence and assessing the evidence they base their decisions on.

In the present study, we searched for methodological papers on the topic of patient heterogeneity. Although our search was systematic, it may not have been comprehensive. Our search terms were restricted to heterogeneity and economic evaluation, and did not include related terms like subgroups, individual or variability. Therefore, only 11 of the 20 included papers were obtained through the initial search. Five additional papers were found by examining the reference lists of the included papers and discussion with the authors, and four additional papers were comments on the included papers. The three papers that described regression techniques to identify or define subgroups [12, 20, 21] were not found in the initial search, but were key publications in the present paper. These papers were probably not found because they did not refer to heterogeneity, but to subgroup analyses. Including more search terms (i.e. subgroup analysis, variability) might have increased the sensitivity of the initial search, but also decreased the specificity. Despite the low sensitivity of the initial electronic search, we are convinced that through searching the reference lists of the included publications and extensive discussion with the authors our literature review was sufficiently thorough and that we have not missed any key publications.

While the present review provides a list of potential methods for use in economic evaluation, it does not result in one preferred method. Because most methods serve different purposes, the choice of method depends more on the data that are available and the purpose (e.g. in the design or analysis of an economic evaluation) than on its quality. However, three different methods were found that all use regression techniques to identify subgroups of patients. In one method, the NMB is the dependent variable [12], while in the method presented in a more recent paper by the same authors costs and effects are separated [20]. Information about whether a patient characteristic influences NMB through costs or effects can be very relevant for decision makers, especially with regard to potential equity concerns. The third method also regards costs and effects as separate dependent variables, but is more flexible than the second method [21]. The advantage of this method is that it does not assume Normal distributions, which may make it more appropriate for real data. However, the disadvantage is that the method is technically more difficult to implement. Other regression techniques that are used in the context of economic evaluation may also be used to explore heterogeneity, but only these three were explicitly suggested in the literature. No studies were found that directly compare different methods. A potential disadvantage of all regression methods is that they require individual patient data, which may not always be available. Regardless of the method that is used, the testing of heterogeneity should be undertaken with due care and diligence.

Two methods were identified that assess the value of acknowledging heterogeneity [9, 10]. The EVIC technique that was proposed by Basu and Meltzer [10] is relatively new and not yet frequently used. Similar to the expected value of perfect information (EVPI), the EVIC represents an upper bound of the monetary gain that can be achieved in theory. In practice, this upper bound may not be reached, as due to variability we may not always be able to predict the optimal treatment for an individual patient (EVIC), just like we will never reach complete certainty (EVPI). A recent application of EVIC indicates that it is a useful and feasible technique on both a clinical and a policy level, especially when considering the EVIC for specific patient characteristics (parameter-specific EVIC) [30]. More studies on either the application or further development of EVIC are needed to support a widespread use of EVIC to assess the value of acknowledging heterogeneity in population reimbursement decisions.

When reflecting patient heterogeneity in economic evaluations and population reimbursement decisions, it is important to be aware of potential equity concerns. As mentioned by Sculpher [7], whether a subgroup policy will be deemed acceptable may depend on whether the heterogeneity in cost effectiveness is caused by differences in treatment effect or in one of the other input parameters.

Patient heterogeneity in treatment effect is expectedly a more acceptable ground for subgroup policy. Also, the source of heterogeneity may be relevant, since a subgroup policy based on differences in clinical characteristics is expectedly more acceptable than a subgroup policy based on patient demographics such as age or race. A special source of patient heterogeneity is individual preferences. While Sculpher and Gafni [23] propose to acknowledge differences in preferences while maintaining the use of utility values of the general public, both Bala and Zarkin [13] and Basu and Meltzer [10] suggest the use of individual preferences to value health state utility. Techniques to reflect heterogeneity in preferences when valuing health state utility are becoming increasingly available [31]. Whether individual preferences should have a role in population reimbursement decisions is however a topic of debate [32–35]. Because of the differences in ethical concerns regarding sources of heterogeneity and the input parameters, it is important that when proposing subgroup policy it is clear which source of heterogeneity is relevant and in which of the input parameters of an economic evaluation this patient heterogeneity occurs. Also, it is important to quantify the potential costs of equity constraints, as proposed by Coyle et al. [9]. With this information policy makers can make a trade-off between efficiency and equity.

From the results of our review, we found that many papers and handbooks recommend to reflect heterogeneity by performing economic evaluations for specific patient groups using stratified analyses. Extensive literature exists on how to define subgroups based on clinical evidence [36–43]. However, this clinical heterogeneity relates to differences on a relative scale (i.e. heterogeneity in measures such as relative risks, odds ratios and hazard ratios) [6, 7]. It was clear from the present review that, since economic evaluations concern absolute benefits, heterogeneity in absolute effectiveness, for example because of differences in baseline risk, health state utility or resource utilization, should also be acknowledged in economic evaluations. That is, homogeneity in treatment effects from a clinical point of view does not necessarily imply homogeneity in cost effectiveness. This is nicely illustrated in cost-effectiveness analyses on cardiovascular disease, where baseline risk was found to cause heterogeneity in the cost effectiveness of the intervention [44, 45]. The framework in Fig. 2 allows researchers to systematically explore whether patient heterogeneity could be relevant in each of the input parameters of an economic evaluation. This allows researchers to consider heterogeneity on an absolute scale. In addition to the difference between heterogeneity in relative versus absolute effects, two other challenges arise when using stratified analyses in economic evaluation. First, it is unclear whether policy makers wish to

implement stratified policy if there is no heterogeneity in the relative treatment effect. By presenting potential subgroups and costs of equity constraints, policy makers can make an informed trade-off between equity and efficiency. Second, if we incorporate stratified analyses in economic evaluations, we are uncertain about the definition of our subgroups, especially when the characteristic is a continuous measure and cut-off points are needed. Ideally this uncertainty should be incorporated in the economic evaluation. For these gaps in current knowledge, future methodological research could generate new knowledge that can be used when conducting economic evaluations.

Pharmacoeconomic guidelines, which present country-specific guidelines for conducting economic evaluations, provide hardly any methodological guidance on acknowledging heterogeneity [11]. As these guidelines have a very different purpose than original methodological articles, and the focus of the current review was on original methodology, we decided not to include them. However, it would be an interesting topic for further research to assess to what extent these guidelines are attuned to the available methodology identified in the current review.

While the present paper contributes to current knowledge, it also highlighted where knowledge was lacking. Although Sculpher [7] made an important attempt in this direction, none of the studies provided guidance on the types of subgroups that should be explored, or how subgroups should be defined. By systematically reviewing the sources of heterogeneity and input parameters where they may occur, and summarizing them in a concise figure, we hope to partly provide such guidance. Also, we have summarized which methods can be used in each phase of an economic evaluation. This may help researchers to systematically consider whether patient heterogeneity should be acknowledged in their economic evaluation, and how this can be done. Our results may be used in the field of comparative effectiveness research, where patient heterogeneity is recognized, but still very much focused on heterogeneity in relative treatment effects [46]. Our results may also facilitate the collection of data within access with evidence development schemes to examine patient heterogeneity [47]. It could help policy makers and researchers to agree upon which evidence to collect, and could foster the acknowledgement of patient heterogeneity, even when an intervention is on average cost effective for the population. In the end, acknowledging patient heterogeneity may well improve the efficiency of healthcare.

5 Conclusion

By systematically reviewing current knowledge regarding patient heterogeneity within economic evaluations of

healthcare programmes, we provide guidance for future economic evaluations. Guidance is provided on which sources of patient heterogeneity to consider, how to acknowledge them in economic evaluation and potential concerns. The improved acknowledgement of patient heterogeneity in future economic evaluations may well improve the efficiency of healthcare.

Acknowledgments This study was financially supported by a research grant (number 152002021) from the Dutch Organisation for Health Research and Development (ZonMw). Janneke Grutters received an unrestricted HTAcademy scholarship prize from Pfizer for this work. The funding organization had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. The authors have no conflicts of interest.

Author contributions JG and MJ had the idea for the paper. JG and MJ planned the work, and performed the initial literature search and analysis and interpretation of the data. MS, AHB, JLS, MC, JES, DDR, AB and BR critically assessed and discussed the literature search, and analysis and interpretation of the data. JG and MJ wrote the paper. MS, AHB, JLS, MC, JES, DDR, AB and BR read several draft versions of the paper and made substantive suggestions for revision. All authors approved the final submitted version. JG acts as a guarantor for the overall content.

References

1. Oxford University Press. Oxford dictionaries. <http://oxforddictionaries.com/>. Accessed 3 Dec 2012.
2. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. New York: Oxford University Press; 2006.
3. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. *Health Technol Assess*. 2004;8(49):iii–iv, 1–192.
4. Bast RC Jr, Hortobagyi GN. Individualized care for patients with cancer: a work in progress. *N Engl J Med*. 2004;351(27):2865–7.
5. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. *Nature*. 2004;429(6990):464–8.
6. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005.
7. Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. *Pharmacoeconomics*. 2008;26(9):799–806.
8. Stevens W, Normand C. Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation. *Soc Sci Med*. 2004;58(2):315–20.
9. Coyle D, Buxton MJ, O'Brien BJ. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. *Health Econ*. 2003;12(5):421–7.
10. Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. *Med Decis Mak*. 2007;27(2):112–27.
11. International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world. Lawrenceville: ISPOR. 2010. <http://www.ispor.org/PEguidelines/index.asp>. Accessed 15 Nov 2010.
12. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. *Health Econ*. 2002;11(5):415–30.
13. Bala MV, Zarkin GA. Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level? *Pharmacoeconomics*. 2004;22(8):495–8.
14. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. *Health Econ*. 2006;15(12):1295–310.
15. Heeg BM, Damen J, Buskens E, Caleo S, de Charro F, van Hout BA. Modelling approaches: the case of schizophrenia. *Pharmacoeconomics*. 2008;26(8):633–48.
16. Hoch JS, Dewa CS. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. *Pharmacoeconomics*. 2007;25(10):807–16.
17. Marshall DA, Hux M. Design and analysis issues for economic analysis alongside clinical trials. *Med Care*. 2009;47(7 Suppl. 1):S14–20.
18. Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. *Stat Med*. 2003;22(23):3687–709.
19. Zaric GS. The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysis. *Med Decis Mak*. 2003;23(5):379–96.
20. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. *Health Econ*. 2004;13(5):461–75.
21. Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. *Health Econ*. 2005;14(12):1217–29.
22. Sculpher M. Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectiveness. *Value Health*. 2010;13(Suppl. 1):S18–21.
23. Sculpher M, Gafni A. Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. *Health Econ*. 2001;10(4):317–24.
24. Bala MV, Zarkin GA. On pharmacogenomics and cost-effectiveness analysis at the individual level. *Pharmacoeconomics*. 2005;23(5):527.
25. La Caze A. Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems? *Pharmacoeconomics*. 2005;23(5):445–7.
26. Robinson A, Parkin D. Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. A response to Sculpher and Gafni. *Health Econ*. 2002;11(7):649–51. (discussion 53–4).
27. Sculpher M, Gafni A. Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Author's reply. *Health Econ*. 2002;11(7):653–4.
28. Barbieri M, Drummond M, Rutten F, Cook J, Glick HA, Lis J, et al. What do international pharmacoeconomic guidelines say about economic data transferability? *Value Health*. 2010;13(8):1028–37.
29. Glick HA, Doshi JA, Sonnad SS, Polsky D, editors. Economic Evaluation in Clinical Trials. Oxford: Oxford University Press; 2007.
30. van Gestel A, Grutters J, Schouten J, Webers C, Beckers H, Joore M, et al. The role of the expected value of individualized care in cost-effectiveness analyses and decision making. *Value Health*. 2012;15(1):13–21.
31. Flynn TN, Louviere JJ, Peters TJ, Coast J. Using discrete choice experiments to understand preferences for quality of life: variance-scale heterogeneity matters. *Soc Sci Med*. 2010;70(12):1957–65.

32. Sculpher M, Gafni A, Watt I. Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions. *Soc Sci Med*. 2002;54(9):1369–77.
33. Dowie J. Towards the equitably efficient and transparently decidable use of public funds in the deep blue millennium. *Health Econ*. 1998;7(2):93–103.
34. Brazier JE, Dixon S, Ratcliffe J. The role of patient preferences in cost-effectiveness analysis: a conflict of values? *Pharmacoeconomics*. 2009;27(9):705–12.
35. Bryan S, Dolan P. Discrete choice experiments in health economics. For better or for worse? *Eur J Health Econ*. 2004;5(3):199–202.
36. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. *Lancet*. 2000;355(9209):1064–9.
37. Rothwell PM. Can overall results of clinical trials be applied to all patients? *Lancet*. 1995;345(8965):1616–9.
38. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. *Health Technol Assess*. 2001;5(33):1–56.
39. Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? *BMJ*. 2001;322(7292):989–91.
40. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. *Ann Intern Med*. 1992;116(1):78–84.
41. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. *Stat Med*. 2002;21(19):2917–30.
42. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. *Lancet*. 2005;365(9454):176–86.
43. Sun X, Briel M, Busse JW, Akl EA, You JJ, Mejza F, et al. Subgroup analysis of trials is rarely easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials. *Trials*. 2009;10:101.
44. Briggs A, Mihaylova B, Sculpher M, Hall A, Wolstenholme J, Simoons M, et al. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. *Heart*. 2007;93(9):1081–6.
45. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. *Lancet*. 2005;365(9473):1779–85.
46. Helfand M, Tunis S, Whitlock EP, Pauker SG, Basu A, Chilingirian J, et al. A CTSA agenda to advance methods for comparative effectiveness research. *Clin Transl Sci*. 2011;4(3):188–98.
47. Briggs A, Ritchie K, Fenwick E, Chalkidou K, Littlejohns P. Access with evidence development in the UK: past experience, current initiatives and future potential. *Pharmacoeconomics*. 2010;28(2):163–70.
48. Fox-Rushby J, Cairns J, editors. *Economic evaluation*. Maidenhead: Open University Press; 2005.
49. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. *Cost-effectiveness in Health and Medicine*. Oxford: Oxford University Press; 1996.